SCHEMBL3343567

SCHEMBL3343567

Cc1nnc(Nc2ccc3c(c2)ncn3-c2ccccc2O)c2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.69
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
HSD17B10 Q99714 2/20 0.48
ALOX15 P16050 1/20 0.48
MAPT P10636 4/20 0.48
KDM4E B2RXH2 3/20 0.48
TDP1 Q9NUW8 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MAPK1 P28482 1/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
ADRA2B P18089 1/20 0.46
ALDH1A1 P00352 3/20 0.45
RXFP1 Q9HBX9 4/20 0.45
POLB P06746 4/20 0.45
ENPP3 O14638 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12135744 0.86 GAA (0.65) GAANPC1RAB9AHSD17B10ALOX15
SCHEMBL12135739 0.86 GAA (0.65) GAAMAPTKDM4ETDP1GPR55
SCHEMBL2308486 0.86 GAA (0.67) GAANPC1RAB9AHSD17B10ALOX15
SCHEMBL2308483 0.85 GAA (0.73) GAANPC1RAB9AHSD17B10ALOX15
Hydrochloric Acid SCHEMBL2309577 0.84 GAA (0.71) GAANPC1RAB9AHSD17B10ALOX15
SCHEMBL13304957 0.83 GAA (0.70) GAANPC1RAB9AHSD17B10ALOX15
SCHEMBL12135730 0.83 GAA (0.70) GAANPC1RAB9AHSD17B10ALOX15
SCHEMBL13304944 0.82 GAA (0.67) GAANPC1RAB9AHSD17B10ALOX15
SCHEMBL13304847 0.82 GAA (0.67) GAANPC1RAB9AHSD17B10ALOX15
SCHEMBL2310755 0.81 GAA (0.58) GAANPC1RAB9AHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION RCOR3, BRD3, BRPF3 GAA 4544/4885NPC1 1400/4885RAB9A 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.